Chapter 4

Margin Reset

Molina's 2025 profit collapse was broad: all three insurance segments saw their medical care ratio rise. The more telling signal is what management did next. Between its November 2024 and May 2026 Investor Days it cut its long-term pre-tax margin target from 4–5% to 2–3% and raised its consolidated MCR target roughly 350 basis points [1] [2]. The evidence points to a structural re-basing of profitability, not the "temporary" imbalance the filings describe.

The medical care ratio — medical costs as a share of premium — is the report's margin pillar because Molina keeps only what is left after claims. At a 91.7% consolidated MCR in 2025, that residual was 8.3 cents per premium dollar before administrative cost, against 10.9 cents in 2024 [3]. This chapter takes that ratio apart by segment, by reserve, and by management's own forward targets, and asks how much of the break reverses.

Every segment turned, and not for the same reason

Molina reports MCR for three insurance segments — Medicaid (about three-quarters of premium), Medicare, and Marketplace. All three deteriorated in 2025, but they tell different stories.

Source: segment medical care ratios as reported, FY2019–FY2025; FY2024–FY2025 figures per the FY2025 10-K segment table [4].

The Medicaid line is the one that matters. For five years it sat in a tight band near 88% — 88.0%, 87.4%, 88.7%, 88.0%, 88.7% from 2019 to 2023 — then stepped to 90.3% in 2024 and 91.8% in 2025 [5]. Management attributes the 150-basis-point 2025 rise to utilization "higher than we expected" across behavioral health, high-cost drugs and long-term services, plus acuity and product-mix shifts and unfavorable California retroactive premium items, "partially offset by premium rate increases" that "have lagged the increase in medical cost trend, resulting in a rate and trend imbalance that we believe to be temporary" [6].

Medicare rose 330 basis points to 92.4%, driven by high-acuity dual-eligible utilization and margin compression in the traditional Medicare Advantage prescription-drug (MAPD) product that Molina has since decided to exit for 2027 [7]. Marketplace is the most volatile and the least representative: its MCR jumped from 75.4% to 90.6%, but 75% was itself an unsustainable level — below the 80% floor the ACA imposes before rebates — inflated by favorable prior years and now hit by high-acuity special-enrollment members, the ConnectiCare acquisition, and CMS program-integrity actions that disenrolled members while Molina still bore their costs [8].

Sources: 2024–2025 actuals, FY2025 10-K [9]; 2026 guidance, Q4/FY2025 earnings release [10]; 2029 targets, 2026 Investor Day [11].

The pattern separates cleanly. Marketplace (guided to 85.5% for 2026 and a 80–85% target) and the loss-making MAPD line (being exited) are the recoverable, largely self-inflicted parts. The Medicaid core is not: management's own 2029 target for it is 91.5%–92.5% — essentially where 2025 landed, and roughly 350 basis points above the level Molina ran for half a decade [12].

Growth without margin

The clearest way to see the damage is in medical margin — premium minus medical costs, the segment profit Molina actually manages. In 2025 the company added $4.4 billion of premium and lost $635 million of medical margin [13].

Source: FY2025 10-K, segment premium and medical margin ($43,052M premium and $3,564M medical margin in 2025 vs $38,627M and $4,199M in 2024) [14].

Source: sum of segment medical margins as reported, FY2020–FY2025; 2024–2025 per the FY2025 10-K [15].

Medical margin had grown every year through 2024. Its 2025 fall is the first break in the series and the mechanism behind the earnings collapse a cold reader met earlier (Business and Thesis): a thin-spread aggregator earns on the gap between premium and cost, and in 2025 the gap narrowed while the book grew.

The reserve cushion that used to flatter the number

A managed-care insurer books claims it has not yet paid as an estimated liability, then trues it up as real claims arrive. When prior estimates prove too high, the excess is released as "favorable prior year development" — a recurring tailwind to the current year's reported medical costs. Molina's tailwind nearly vanished in 2025.

Source: FY2025 10-K, Medical Claims and Benefits Payable reconciliation — favorable prior-year development of $427M (2023), $675M (2024) and $98M (2025) [16]. Percentages are development as a share of that year's opening reserve.

Favorable development fell from $675 million in 2024 to $98 million in 2025 — from 16.1% of opening reserves to 2.1% [17]. This matters twice. First, the 2024 baseline against which the break is measured was itself flattered: a $675 million release is worth about 1.7 points of 2024 premium, so the "clean" 2024 ratio was closer to 91% than the reported 89.1% suggests, and the true year-on-year deterioration is smaller only because 2024 was better than it looked. Second, Marketplace flipped from favorable to $61 million of adverse development in 2025 — its 2024 reserves proved too low — which is what happens when a book grows fast into a deteriorating risk pool [18].

The fourth quarter carried the strain. Q4 2025 MCR reached 94.6% and the company reported a GAAP loss of $3.15 per share (an adjusted loss of $2.75), as the California retroactive items and reserve strengthening landed [19]. For the full year, adjusted diluted EPS fell to $11.03 from $22.65 [20].

Management re-based its own targets

The strongest evidence on the "temporary versus structural" question is not in any single ratio; it is in the targets management sets for itself. In November 2024, Molina's stated three-year plan carried a consolidated medical-cost ratio of 87.5%–88.5% and a pre-tax margin of 4%–5% — the same 4%–5% range it had held as a long-term target for years and delivered (4.7%) across 2019–2024 [21] [22]. Eighteen months later, the 2029 targets set a consolidated MCR of 91%–92% and an adjusted pre-tax margin of 2%–3% [23].

Sources: 2024 Investor Day targets [24]; 2029 targets, 2026 Investor Day [25] [26]. Medicaid pre-2024 run-rate is the ~88% five-year band from the segment trail above.

Cutting a multi-year pre-tax margin target roughly in half is not the language of a passing dislocation. It is a company telling investors that the profitability of a government premium dollar has permanently stepped down — from roughly a nickel of pre-tax margin to two or three cents. The near term confirms the direction: management's own 2026 guidance projects consolidated MCR rising again to 92.6%, with Medicaid at 92.9% and Medicare at 94.0%, and adjusted EPS of only "at least $5.00" [27]. The first quarter of 2026 was consistent — a 91.1% consolidated MCR, net income of $14 million, and a $93 million impairment tied to the MAPD exit — with segment ratios of 92.0% Medicaid, 89.8% Medicare and 84.0% Marketplace [28] [29]. There is no snap-back in the data yet.

What is temporary, and what is not

The measured read is that the break is largely structural at the margin level and largely recoverable at the earnings level — two different statements that are easy to conflate.

Structural: the normalized medical-cost ratio, on management's own targets, has re-based about 350 basis points higher and the pre-tax margin has roughly halved, led by a Medicaid core whose 2029 target sits at 2025's elevated level [30] [31]. An investor should stop modelling Molina as an 88%-MCR, 4–5%-pre-tax business and start modelling a 91–92%-MCR, 2–3%-pre-tax one.

Recoverable: absolute earnings can still climb even if the margin does not. Management's bridge from the 2026 floor of "at least $5.00" to a 2029 target of $25.00 leans on premium growth, operating leverage, the Marketplace and MAPD clean-up, M&A and buybacks — and states explicitly that it "requires only a modest improvement in the Medicaid rate and trend imbalance" [32]. In other words, the plan does not depend on Medicaid MCR returning to 88%; it depends on growing volume against a lower unit margin.

Sources: FY2024–FY2025 actual and FY2026 guidance ("at least $5.00"), Q4/FY2025 earnings release [33] [34]; FY2029 target of $25.00, 2026 Investor Day [35].

Three things would change this read, and each is falsifiable in a filing. First, the Medicaid rate updates that states set for 2026 and 2027: if premium rate increases begin to catch cost trend, the "imbalance" thesis gains support and consolidated MCR should peak near the guided 92.6% and turn. Second, quarter-by-quarter consolidated MCR through 2026 in the 10-Qs — a decline below the guided path would be genuine evidence of the temporary case. Third, prior-year reserve development in the 2026 disclosures: another step down, or a turn to adverse beyond Marketplace, would signal that 2025 reserves were set too tight and that reported margins still overstate the run-rate [36]. Until those move, the prudent base case treats the lower margin as the new normal and the earnings recovery as a growth-and-leverage story that must be earned, not a margin snap-back that can be assumed.